top of page

ASCO 2026: Olema Oncology's CEO Sean Bohen highlights new KAT6 data in breast and prostate cancer, and updates us on the progress of palazestrant's pivotal trials

  • May 30
  • 1 min read

He discusses the potential utility of KAT6 after presenting monotherapy data, and how it could be used in combination with palazestrant (a complete estrogen receptor antagonist). Plus, learning from the field in the estrogen receptor space, and an update on the progress of Olema's own pivotal tirals. The company's OPERA-1 monotherapy phase 3 of palazestrant is schedule to read in the fall.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page